|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006118,
umls-concept:C0007257,
umls-concept:C0039593,
umls-concept:C0076080,
umls-concept:C0087111,
umls-concept:C0205265,
umls-concept:C0334579,
umls-concept:C0446516,
umls-concept:C0473169,
umls-concept:C0920321,
umls-concept:C1514695,
umls-concept:C1522449,
umls-concept:C1555582,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-7-5
|
|
pubmed:abstractText |
To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
pubmed-author:AtkinsJJ,
pubmed-author:BaharyJean-PaulJP,
pubmed-author:BargerGeoffreyG,
pubmed-author:BucknerJanJ,
pubmed-author:BushunowPeterP,
pubmed-author:CairncrossGregoryG,
pubmed-author:ChangSusan MSM,
pubmed-author:ChoucairAliA,
pubmed-author:CurranWalterW,
pubmed-author:DolinskasCarolC,
pubmed-author:GilbertMarkM,
pubmed-author:KressCC,
pubmed-author:LouisDavid NDN,
pubmed-author:MehtaMineshM,
pubmed-author:SeiferheldWendyW,
pubmed-author:ShareRR,
pubmed-author:ThoronLouisaL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1122-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
|
|
pubmed:affiliation |
Department of Neurological Surgery, University of California San Francisco, School of Medicine, 400 Parnassus Avenue A808, San Francisco, CA 94143, USA. changs@neurosurg.ucsf.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
